|
Age, years, ≥70 vs. <70
|
0.857 (0.539–1.362)
|
0.513
| | |
|
Sex, men vs. women
|
1.354 (0.814–2.255)
|
0.243
| | |
|
BMI, kg/m2, ≥25.0 vs. <25.0
|
0.731 (0.444–1.204)
|
0.218
| | |
|
Baseline L3 SMI, low SMI vs. high SMI
|
1.405 (0.861–2.293)
|
0.174
| | |
|
ΔL3 SMI, SML vs. non-SML
|
1.750 (1.093–2.800)
|
0.020
|
1.675 (1.031–2.721)
|
0.037
|
|
ALT, U/L, ≥30 vs. <30
|
1.046 (0.650–1.682)
|
0.854
| | |
|
Total bilirubin, mg/dL, ≥1.5 vs. <1.5
|
1.690 (1.002–2.851)
|
0.049
|
1.747 (0.897–3.403)
|
0.101
|
|
Albumin, g/dL, ≥3.5 vs. <3.5
|
0.595 (0.361–0.982)
|
0.042
|
0.697 (0.386–1.259)
|
0.231
|
|
Platelet count, ×104/μL, ≥10.0 vs. <10.0
|
0.971 (0.607–1.552)
|
0.902
| | |
|
Child-Pugh classification, A vs. B
|
0.638 (0.395–1.030)
|
0.066
| | |
|
AFP, ng/mL, ≥20 vs. <20
|
2.618 (1.615–4.241)
|
< 0.001
|
2.550 (1.440–4.515)
|
0.001
|
|
TNM stage, I + II vs. III + IV
|
0.785 (0.474–1.300)
|
0.347
| | |
|
Maximum tumor diameter, mm, ≥30 vs. <30
|
1.936 (1.195–3.135)
|
0.007
|
1.925 (1.166–3.179)
|
0.010
|
|
Number of tumors, solitary vs. multiple
|
0.961 (0.572–1.614)
|
0.880
| | |
|
Treatment sessions between CT exams, sessions, 1 vs. ≥ 2
|
0.696 (0.433–1.119)
|
0.135
| | |
|
mRECIST assessment, non-PD vs. PD
|
0.444 (0.277–0.712)
|
0.001
|
0.653 (0.392–1.088)
|
0.102
|
|
BCAA supplementation, presence vs. absence
|
1.614 (0.898–2.900)
|
0.110
| | |
